Rashmi Chugh

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model
    Rashmi Chugh
    1500 E Medical Center Dr, C407 Med Inn, SPC 5843, Ann Arbor, MI 48109 5843, USA
    J Clin Oncol 27:3148-53. 2009
  2. ncbi Pharmacotherapy of sarcoma
    Rashmi Chugh
    University of Michigan, C407 Med Inn Building, 1500 E Medical Center Dr, SPC 5848, Ann Arbor, MI 48109 5848, USA
    Expert Opin Pharmacother 10:1953-63. 2009
  3. ncbi Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
  4. ncbi Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer 109:2315-22. 2007
  5. ncbi Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
  6. ncbi Dose--effect relationships for femoral fractures after multimodality limb-sparing therapy of soft-tissue sarcomas of the proximal lower extremity
    Daniel Pak
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 83:1257-63. 2012
  7. ncbi Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma
    Rashmi Chugh
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 23:3597-604. 2005
  8. ncbi Chordoma: the nonsarcoma primary bone tumor
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, 24 Frank Lloyd Wright Drive, A3400, P O Box 483, Ann Arbor, Michigan 48106, USA
    Oncologist 12:1344-50. 2007
  9. ncbi Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity
    Aaron Sabolch
    University of Michigan Medical School, Ann Arbor, USA
    Am J Clin Oncol 35:151-7. 2012
  10. ncbi Experimental therapies and clinical trials in bone sarcoma
    Rashmi Chugh
    Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109 5843, USA
    J Natl Compr Canc Netw 8:715-25. 2010

Detail Information

Publications12

  1. ncbi Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model
    Rashmi Chugh
    1500 E Medical Center Dr, C407 Med Inn, SPC 5843, Ann Arbor, MI 48109 5843, USA
    J Clin Oncol 27:3148-53. 2009
    ..Although rare dramatic responses were seen, imatinib is not an active agent in advanced sarcoma in these subtypes...
  2. ncbi Pharmacotherapy of sarcoma
    Rashmi Chugh
    University of Michigan, C407 Med Inn Building, 1500 E Medical Center Dr, SPC 5848, Ann Arbor, MI 48109 5848, USA
    Expert Opin Pharmacother 10:1953-63. 2009
    ..The clinical and biologic heterogeneity of the > 50 histologic subtypes of sarcomas often require different therapeutic approaches...
  3. ncbi Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial
    Rashmi Chugh
    Department of Internal Medicine, University of Michigan, Ann Arbor, 48109 5843, USA
    Clin Cancer Res 16:4884-91. 2010
    ..Here, we report specifically on the outcome of patients with AF as well as evaluations undertaken to examine the mechanism of imatinib...
  4. ncbi Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer 109:2315-22. 2007
    ..The pharmacokinetics of ifosfamide and CYP3A measurements observed are reported...
  5. ncbi Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
    Scott M Schuetze
    Division of Hematology Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109 5848, United States
    Eur J Cancer 48:1347-53. 2012
    ..The combination of sirolimus and cyclophosphamide demonstrated synergistic anti-sarcoma activity in preclinical models; therefore, we conducted a phase II trial of sirolimus and cyclophosphamide in patients with advanced sarcoma...
  6. ncbi Dose--effect relationships for femoral fractures after multimodality limb-sparing therapy of soft-tissue sarcomas of the proximal lower extremity
    Daniel Pak
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 83:1257-63. 2012
    ..We investigated the clinical and dosimetric predictors for radiation-associated femoral fractures in patients with proximal lower extremity soft tissue sarcomas (STS)...
  7. ncbi Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma
    Rashmi Chugh
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 23:3597-604. 2005
    ..CONCLUSION: 9-NC has modest activity in delaying progression in patients with unresectable or metastatic chordoma. 9-NC is associated with moderate toxicity and shows little benefit in patients with advanced STS and GIST...
  8. ncbi Chordoma: the nonsarcoma primary bone tumor
    Rashmi Chugh
    Department of Internal Medicine, Division of Hematology Oncology, 24 Frank Lloyd Wright Drive, A3400, P O Box 483, Ann Arbor, Michigan 48106, USA
    Oncologist 12:1344-50. 2007
    ..Radiation therapy may also salvage some patients with local recurrence. One series reported a 2-year actuarial local control rate of 33% for patients treated with proton beam irradiation...
  9. ncbi Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity
    Aaron Sabolch
    University of Michigan Medical School, Ann Arbor, USA
    Am J Clin Oncol 35:151-7. 2012
    ....
  10. ncbi Experimental therapies and clinical trials in bone sarcoma
    Rashmi Chugh
    Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan 48109 5843, USA
    J Natl Compr Canc Netw 8:715-25. 2010
    ..This article discusses recently completed and currently enrolling clinical trials for the 3 most common bone sarcomas: osteosarcoma, Ewing's sarcoma family tumors, and chondrosarcoma...
  11. ncbi Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma
    Francis P Worden
    Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 23:105-12. 2005
    ..These results suggest that HD ifosfamide combination regimens should not be used as first-line therapy for patients with STS...
  12. ncbi Nonepithelial malignancies of the breast
    Rashmi Chugh
    Department of Internal Medicine, Cancer Center University of Michigan, Ann Arbor, Michigan 48109, USA
    Oncology (Williston Park) 18:665-73; discussion 673-6. 2004
    ..This review discusses various features of these uncommon malignancies and their treatment, with the goal of increasing understanding of their clinical behavior and management...